CMS Open Payments · Program Year 2024
Dutch Ophthalmic, USA
Dutch Ophthalmic, USA reported $85,026.86 across General Payments, Research, and Ownership to 371 physicians and teaching hospitals across 371 transactions.
- $85.0K
- All-tracks total
- 371
- Transactions
- 371
- Recipients
- −$89.4K
- General Payments vs PY2023
Dutch Ophthalmic, USA reported $85,026.86 across all CMS Open Payments tracks (General + Research + Ownership) to 371 physicians and teaching hospitals in Program Year 2024 - ranking #1226 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $85,026.86, averaging $229.18 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer dutch-ophthalmic-usa Dutch Ophthalmic, USA
$85.0K · #1226/1,925 · 0.0% industry · PY2024
- TOT $85.0K
- RANK #1226
- SHARE 0.0%
- TXN 371
- RCP 371
- CAT 4
- GEN $85.0K
- ΔGEN −$89.4K
- TOP1 12.1%
- PY 2024
Volume peers
Nearest volume peer: EnsoData, Inc. ($85.1K)
Dutch Ophthalmic, USA sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Dutch Ophthalmic, USA's CMS-reported General Payments decreased by $89.4K (−51.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: DUTCH OPHTHALMIC, USAPY2023: DUTCH OPHTHALMIC, USAPY2024: Dutch Ophthalmic, USA. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $174,381.10
- PY2024
- $85,026.86
What the Data Shows for Dutch Ophthalmic, USA
In Program Year 2024, Dutch Ophthalmic, USA reported $85,026.86 in payments to 371 physicians and teaching hospitals across 371 individual transactions, an average of $229.18 per transaction and $229.18 per recipient. That total places Dutch Ophthalmic, USA at rank #1226 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 4 general-payment categories charted below, "Travel and Lodging" is the largest at $39.2K across 42 transactions, 46.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Dutch Ophthalmic, USA made 4 types of general payments. "Travel and Lodging" is the largest category at $39.2K, 46.1% of General Payments.
Dutch Ophthalmic, USA reports 4 general-payment categories - the top three are Travel and Lodging (46.1%), Food and Beverage (32.6%), and Consulting Fee (20.7%). The remaining 1 category make up 0.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Dutch Ophthalmic, USA divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $39.2K | 42 | 46.1% |
| Food and Beverage | $27.7K | 323 | 32.6% |
| Consulting Fee | $17.6K | 5 | 20.7% |
| Education | $477.00 | 1 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $30,004.06 (35.3%) of $85,026.86 in this company's General Payments records across 261 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Dutch Ophthalmic, USA
The five named recipients with the highest reported General Payments from this company
- 1
Asheesh Tewari
$10,292.51 across 3 reported transactions
- 2
Courtney M Crawford
$6,104.38 across 9 reported transactions
- 3
Dilraj S Grewal
$5,832.58 across 2 reported transactions
- 4
Christopher D Riemann
$4,080.93 across 4 reported transactions
- 5
Gaurav K Shah
$3,693.66 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Dutch Ophthalmic, USA's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Dutch Ophthalmic, USA.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Dutch Ophthalmic, USA.
Showing 6 of 1,924 companies with CMS-reported payment data.
Samsung Bioepis Co., Ltd.
Gemini Mountain Medical, LLC
Pramand LLC
Richard Wolf Medical Instruments Corp.
Collagen Matrix, Inc
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.